There are four different types of PPTA membership: Global, Regional, Source, and Associate.
Global membership is available to businesses or groups of businesses engaged in the manufacture of plasma protein therapies that meet the following criteria:
Regional membership (i.e., Europe, North America) is available and limited to businesses or groups of businesses engaged in the manufacture of products in two or fewer continents that meet each of the following criteria:
Source Membership is available to organizations engaged in the collecting, manufacturing, processing or distributing of plasma for further manufacture and that adhere to the highest standards of conduct as described in the Code of Ethics.
Associate Membership is available to organizations or groups of organizations providing services to businesses or organizations that qualify for either Global, Regional or Source membership in the Association. Associate members shall not be eligible to vote on Association matters or to hold office as directors or officers of the Association.
For information on how to become a member of PPTA, contact the Membership Services office of PPTA, by calling 202-789-3100 or by emailing email@example.com.
The following is a final summary of the PPTA-FDA Liaison Meeting held virtually on September 14, 2022.
Welcome, Introductions & Meeting Guidelines
PPTA and Head of Global Plasma welcomed all participants and appreciated FDA’s participation in today’s meeting. PPTA’s Head of Global Regulatory Policy opened the meeting with introductory remarks. PPTA’s External Legal Counsel advised the participants on the meeting guidelines and the antitrust statement.Read More
ANNAPOLIS, MD (October 3, 2022) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the 10th annual International Plasma Awareness Week (IPAW), which will run from Monday, October 3 until Friday, October 7. Hundreds of thousands of people in the U.S. who live with these rare diseases, and countless others facing trauma and emergency medical needs every day, rely on plasma-derived therapies that are only available because of the commitment of dedicated plasma donors.Read More
PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)
Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.Read More
The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.